Article Text

Download PDFPDF

Highlights from this issue
  1. Harminder S Dua,
  2. Arun D Singh, Editors-in-Chief

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Imiquimod 5% cream versus radiotherapy for eyelid BCC

Garcia-Martin et al compared the efficacy, cosmesis and tolerance of two non-surgical treatments – imiquimod (IMQ) 5% cream and radiotherapy (RT) – to combat periocular nodular basal cell carcinoma (BCC) in 27 patients with clinical and histopathological diagnosis randomised to receive IMQ 5% cream once daily, 5 days/week for 6 weeks (15) or RT (fractionated, total dose 40–70 Gy) (12). All tumours showed histopathological remission within 3 months and sustained clinical remission was documented in each patient at 24 months. Overall, cosmesis and functional results were better with IMQ, while RT was better tolerated. See page 1393.

Keratopigmentation for iris defects

Alio et al investigated the functional and cosmetic outcomes of keratopigmentation (KTP) in 11 eyes with visual dysfunction due to iris defects. Micronised mineral pigments were applied intrastromally assisted with femtosecond laser. …

View Full Text

Linked Articles